Cellular immune activation via circulating antibodies for the treatment of chronic diseases
| Reference number | |
| Coordinator | Uppsala universitet - Institutionen för immunologi, genetik och patologi |
| Funding from Vinnova | SEK 2 000 000 |
| Project duration | April 2014 - March 2017 |
| Status | Completed |
Important results from the project
The project initially aimed at an in vivo proof-of-concept for the use of a synthetic peptide-based vaccine for the treatment of disseminated cancer. The uniqueness of our peptide vaccine is a patented peptide sequence from tetanus toxin linked to the peptides that activate our cellular immune system. In this way we improve the uptake of the vaccine into immune cells along with their proper activation, with the aim to target cancer. The project has gone thru several PoC studies and the plans are set for clinical trial entry thru an identified and booked toxicity and clinical trial program.
Expected long term effects
We have identified the mechanism underlying the technology and has also identified the building blocks that optimize its performance. We have identified a drug candidate and nailed a toxicological program and is in the final phase of the GMP production. We have together with consultants identified the regulatory path in the US and the EU, together with expertise within conjugation chemistry identified the way forward to secure stable product for the clinic. Thru these results we have performed PoC and prepared the vaccine candidate for clinical trial initiation.
Approach and implementation
The BIOX program has allowed our academic innovation to become a drug candidate. With the help of a team of translational researchers and entrepreneurs along with consultants we have a new innovation that Immuneed Ab will bring into clinical use. We have identified a conjugation method to generate stable GMP conjugates and we have worked with consultants to identify the regulatory path forward and developed a toxicology program and also a clinical program. We have actively identified and secured money from investors have therefore industry partnership has not been required.